

Michael Cecchini

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8858255/publications.pdf>

Version: 2024-02-01

20
papers

285
citations

1478280

6
h-index

1125617

13
g-index

21
all docs

21
docs citations

21
times ranked

396
citing authors

#	ARTICLE	IF	CITATIONS
1	Targeted Therapies in Advanced Gastric Cancer. <i>Current Treatment Options in Oncology</i> , 2020, 21, 70.	1.3	133
2	Chemotherapy induced neutropenia at 1-month mark is a predictor of overall survival in patients receiving TAS-102 for refractory metastatic colorectal cancer: a cohort study. <i>BMC Cancer</i> , 2016, 16, 467.	1.1	57
3	Challenges with Novel Clinical Trial Designs: Master Protocols. <i>Clinical Cancer Research</i> , 2019, 25, 2049-2057.	3.2	35
4	Microsatellite Instability and KRAS Mutation in Stage IV Colorectal Cancer: Prevalence, Geographic Discrepancies, and Outcomes From the National Cancer Database. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2021, 19, 307-318.	2.3	17
5	Immune therapy of metastatic melanoma developing after allogeneic bone marrow transplant. , 2015, 3, 10.		11
6	Margin negative resection and pathologic downstaging with multiagent chemotherapy with or without radiotherapy in patients with localized pancreas cancer: A national cancer database analysis. <i>Clinical and Translational Radiation Oncology</i> , 2021, 27, 15-23.	0.9	8
7	Yale Cancer Center Precision Medicine Tumor Board: two patients, one targeted therapy, different outcomes. <i>Lancet Oncology, The</i> , 2018, 19, 23-24.	5.1	7
8	A phase 1b expansion study of TAS-102 with oxaliplatin for refractory metastatic colorectal cancer. <i>Cancer</i> , 2021, 127, 1417-1424.	2.0	5
9	Introduction to the Yale Precision Medicine Tumor Board. <i>Lancet Oncology, The</i> , 2018, 19, 19-20.	5.1	3
10	Publication Bias in Gastrointestinal Oncology Trials Performed over the Past Decade. <i>Oncologist</i> , 2021, 26, 660-667.	1.9	3
11	<i>EGFR</i> Exon 19 Deletion in Pancreatic Adenocarcinoma Responds to Erlotinib, Followed by <i>T790M</i> -Mediated Resistance. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2017, 15, 1085-1089.	2.3	2
12	Mutational signature profiling classifies subtypes of clinically different mismatch-repair-deficient tumours with a differential immunogenic response potential. <i>British Journal of Cancer</i> , 2022, , .	2.9	2
13	Can a simplified CT response criteria for vascular involvement in pancreatic adenocarcinoma after neoadjuvant therapy predict survival in patients who achieved subsequent R0 resection?. <i>Abdominal Radiology</i> , 2021, 46, 5609-5617.	1.0	1
14	Clinical outcomes of first line FOLFIRINOX vs. gemcitabine plus nab-paclitaxel in metastatic pancreatic cancer at the Yale Smilow Hospital System. <i>Journal of Gastrointestinal Oncology</i> , 2021, 12, 2547-2556.	0.6	1
15	Stage IV gastrointestinal stromal tumors: Epidemiology, treatment and outcomes in adult US patients.. <i>Journal of Clinical Oncology</i> , 2021, 39, 462-462.	0.8	0
16	Yale Cancer Center Precision Medicine Tumor Board: molecular findings alter a diagnosis and treatment plan. <i>Lancet Oncology, The</i> , 2021, 22, 306-307.	5.1	0
17	Timing and location of palliative care consultation in metastatic pancreatic cancer: A retrospective, single-center observational study.. <i>Journal of Clinical Oncology</i> , 2020, 38, 770-770.	0.8	0
18	Clinical outcomes of first-line FOLFIRINOX versus gemcitabine plus nab-paclitaxel in metastatic pancreatic cancer at the Yale Smilow Healthcare System.. <i>Journal of Clinical Oncology</i> , 2020, 38, 769-769.	0.8	0

#	ARTICLE	IF	CITATIONS
19	QIM22-192: Mismatch Repair Protein Immunohistochemistry: Quality of Mismatch Repair Deficiency Detection. Journal of the National Comprehensive Cancer Network: JNCCN, 2022, 20, QIM22-192.	2.3	0
20	Making National Cancer Instituteâ€™ Designated Comprehensive Cancer Center Knowledge Accessible to Community Oncologists via an Online Tumor Board: Longitudinal Observational Study. JMIR Cancer, 2022, 8, e33859.	0.9	0